论文部分内容阅读
目的观察泰素帝联合联合顺铂(DP方案)与长春瑞滨联合顺铂(NP方案)治疗晚期非小细胞肺癌的近期疗效、毒副反应。方法70例晚期非小细胞肺癌患者随机分组,DP组34例,NP组36例,化疗2周期后评价疗效。结果总有效率DP组41.2%,NP组36.1%,1年生存率DP组47.1%,NP组44.4%,两组比较均无显著性差异(P>0.05)。Ⅲ～Ⅳ度白细胞下降率DP组11.8%,NP组36.1%,有显著差异(P<0.01);Ⅲ～Ⅳ度恶心、呕吐发生率DP组11.8%,NP组33.3%,有显著性差异(P<0.01)。结论DP方案和DP方案治疗晚期NSCLC近期疗效肯定且相似,1年生存率相似,但DP组严重的骨髓抑制及严重的胃肠反应发生率均低于NP组,患者更易耐受DP化疗方案。
Objective To observe the short-term curative effect and toxicity of taxotere in combination with cisplatin (DP) and vinorelbine plus cisplatin (NP) in the treatment of advanced non-small cell lung cancer. Methods Seventy patients with advanced non-small cell lung cancer were randomly divided into three groups: 34 cases in DP group and 36 cases in NP group. After 2 cycles of chemotherapy, the curative effect was evaluated. Results The total effective rate was 41.2% in DP group and 36.1% in NP group. The 1-year survival rate was 47.1% in DP group and 44.4% in NP group. There was no significant difference between the two groups (P> 0.05). Ⅲ ~ Ⅳ degree of leukopenia in the DP group was 11.8%, NP group 36.1%, there was a significant difference (P <0.01); Ⅲ ~ Ⅳ degree of nausea and vomiting incidence of DP group 11.8%, NP group 33.3%, a significant difference P <0.01). Conclusion The DP regimen and DP regimen in the treatment of advanced non-small cell lung cancer (NSCLC) have definite and similar curative effects in recent years. The 1-year survival rates are similar. However, severe myelosuppression and severe gastrointestinal reactions in DP group are lower than those in NP group. Patients are more likely to tolerate DP chemotherapy.